AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04603027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule
Trial: NCT01619969
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules of identical appearance containing starch
Trial: NCT00994968
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00994968
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01282619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo orally twice a day
Trial: NCT03291366
Drug: UCMSCC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion of aUCMSC and conventional therapy
Trial: NCT03291366
Drug: conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional treatment
Trial: NCT00854113
Drug: EGT0001474
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ascending doses given daily as capsules for up to 14 days
Trial: NCT00854113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match EGT0001474
Trial: NCT00942097
Drug: Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CH 12 preparation, 6 drops, twice a day, 4 days per week, until the end of pregnancy. One medication per appointment.
Trial: NCT00942097
Drug: Homeopathy and Nutritional oriented diet
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathy 6 drops twice a day 4 days per week, active and placebo and Balanced nutritional oriented diet for both groups.
Trial: NCT02767349
Drug: MNK-155
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 or 3 tablets initial dose, followed by two tablets every twelve hours
Trial: NCT03060980
Drug: ITCA 650 20/60 mcg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITCA 650 osmotic mini-pump delivering exenatide 20/60 mcg/day
Trial: NCT01795170
Drug: Pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will be on 15-30 mg/kg/day of pyridoxine therapy up to a maximum of 500mg/day divided in 2-3 doses enterally
Trial: NCT00422864
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.
Trial: NCT00422864
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
Trial: NCT00950859
Drug: GSK1349572 (Cohort I)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg once daily
Trial: NCT00950859
Drug: GSK1349572 (Cohort II)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg twice daily
Trial: NCT03398083
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill capsule
Trial: NCT00478218
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m2 administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles) OR 300 mg administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles)
Trial: NCT03062540
Drug: Placebo SL Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
Trial: NCT03184467
Drug: Normal Saline 0.9%
RxNorm normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.9% is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
Trial: NCT01900717
Drug: LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02446899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion (IV)
Trial: NCT02871908
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02074410
Drug: OMS643762
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02074410
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03184467
Drug: GV1001 1.12 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GV1001 1.12 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
Trial: NCT02325414
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous infusion of zoledronic acid 5 mg.
Trial: NCT02325414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) infusion to match zoledronic acid
Trial: NCT02469545
Drug: Crystalline cellulose powder
RxNorm normalized name: cellulose Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and placebo of probiotic - 2x1 placebo caps. filled with micro-crystalline cellulose powder for 8 weeks.
Trial: NCT00330967
Drug: 20% Intralipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lipid infusion
Trial: NCT04591600
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care~* Acetaminophen 500mg on need~* Vitamin C 1000mg twice/ day~* Zinc 75-125 mg/day~* Vitamin D3 5000IU/day~* Azithromycin 250mg/day for 5 days~* Oxygen therapy/ C-Pap if needed~* dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed~* Mechanical ventilation, if needed
Trial: NCT04211909
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg FDC tablet orally once daily.
Trial: NCT04211909
Drug: SOF/VEL/VOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100/100 mg FDC tablet orally once daily.
Trial: NCT00721513
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01652534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar Pill
Trial: NCT01035801
Drug: IN-105
RxNorm normalized name: POLOXAMER 105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prandial Oral Insulin
Trial: NCT01019083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given according to randomization list
Trial: NCT01019083
Drug: Zinc Sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc Sulphate will be given according to randomization list
Trial: NCT03103334
Drug: Methotrexate Biodim®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of methotrexate solution 25 mg/mL for subcutaneous injection with a conventional needle and syringe injection
Trial: NCT00798161
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT01255683
Drug: oral corticosteroid taper
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study in which patients self-select oral steroid treatment for symptoms of CRS. Drug treatments are NOT assigned in this investigation.
Trial: NCT02541396
Drug: Wafermine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 or 70 mg ketamine in a sublingual wafer
Trial: NCT02541396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule or placebo wafer
Trial: NCT02170415
Drug: Protective analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the intervention arm of the study (if no contraindications exist) will be administered one pre-procedure dose of 150mg of oral pregabalin.~For a total of five days post-procedure the participants in the intervention limb of the study will take oral pregablin twice daily at a dose of 75mg twice a day.
Trial: NCT02283762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-titration
Trial: NCT00540332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV dose of placebo, 3 days before the start of RT, then once weekly placebo doses at the same dose during a planned 6 week RT course.
Trial: NCT00202878
Drug: ezetimibe/simvastatin
RxNorm normalized name: EZETIMIBE/SIMVASTATIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/simvastatin 10/40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
Trial: NCT00202878
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
Trial: NCT00202878
Drug: Placebo for simvastatin 40 mg
RxNorm normalized name: simvastatin 40 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one or two tablets orally daily
Trial: NCT00202878
Drug: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet orally daily.
Trial: NCT00685568
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally, twice daily for 3 months; 50 mg tablets. Celecoxib escalating doses starting at 4 mg/kg/day.
Trial: NCT01409811
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT01098513
Drug: GSK1349572 formulation AW
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1349572 formulation AW 50 mg single dose in Part A and 75 to 200 mg fasted or with moderate or high fat meal in Part B.
Trial: NCT02273804
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be taken orally following to the same dose regimen according to theoretical weight
Trial: NCT04621227
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg single dose
Trial: NCT01745497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equivalent volume of liquid with similar color and taste.
Trial: NCT00241189
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00329355
Drug: sumatriptan succinate/naproxen sodium
RxNorm normalized name: sumatriptan succinate/naproxen sodium 10 mg-60 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04292418
Drug: Tacrolimus capsule , mycophenolic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test for study group 1 and study group 2
Trial: NCT00785382
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose Placebo
Trial: NCT00295373
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01297491
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib was supplied as 10mg or 50mg capsules. It was administered on a continuous once daily dosing schedule at a dose of 100 mg. The patient was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area.
Trial: NCT01805791
Drug: HMPL-004 1800 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the arm of HMPL-004 1800 mg/day will receive HMPL-004 600 mg TID (total dose 1800 mg/day) for 56 days (8 weeks).
Trial: NCT01805791
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the arm of Placebo will receive matching Placebo three times daily for 56 days (8 weeks).
Trial: NCT01805791
Drug: HMPL-004 2400 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the arm of HMPL-004 2400 mg/day will receive HMPL-004 800 mg TID (total dose 2400 mg/day) for 56 days (8 weeks).
Trial: NCT01829321
Drug: GLPG0974
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule in the morning and 1 capsule in the evening with food during 28 days
Trial: NCT01829321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule in the morning and 1 capsule in the evening with food during 28 days
Trial: NCT02434029
Drug: Placebo orodispersible tablet twice daily
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01243580
Drug: AG200-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG200-15 is a transdermal contraceptive delivery system delivering 100 - 120 mcg of LNG and 25 - 30 mcg EE
Trial: NCT02004678
Drug: DS-1150b
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00312195
Drug: Placebo to match BTDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match buprenorphine transdermal patch applied for 7-day wear.
Trial: NCT02951182
Drug: Matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03655249
Drug: Aerosoltherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized drugs are individualized for each participants, in line with current standardized practice in our hospital. Those drugs will not be modified for the purpose of this study.
Trial: NCT02858505
Drug: 27 mg elemental iron
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02858505
Drug: 54 mg elemental iron
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03841331
Drug: Matching Placebo Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablets
Trial: NCT03089905
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental arm: loading dose: 1 mcg/kg, infusion starting at 0.1 mcg/kg/min or greater.
Trial: NCT03739125
Drug: CKD-501 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
Trial: NCT03739125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
Trial: NCT01348516
Drug: KM-023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -KM-023 is dosed orally via 75 mg tablets. Study doses are 75 mg, 150 mg, 300 mg, and 600 mg QD for 1 (SAD) or 7 (MAD) days.
Trial: NCT01348516
Drug: Placebo for KM-023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -Placebo for KM-023 is dosed orally via Placebo for KM-023 tablets. Study doses are 1, 2, 3, and 4 placebo tablets QD for 1 (SAD) or 7 (MAD) days.
Trial: NCT02100696
Drug: Etrozulimab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 105 mg etrolizumab administered by SC injection Q4W.
Trial: NCT02100696
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo (matched with etrolizumab) administered by SC injection Q4W.
Trial: NCT00424541
Drug: SPP100 (aliskiren)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00492128
Drug: Losartan/amlodipine or losartan/hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50mg/amlodipine 5mg and the fixed dose combination drug of losartan 50mg/hydrochlorothiazide 12.5mg once a day during 12 months.
Trial: NCT01120717
Drug: QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules for inhalation, delivered by an SDDPI
Trial: NCT01120717
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules for inhalation, delivered by an SDDPI
Trial: NCT04411030
Drug: ASTX660
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form: capsule; Route of administration: oral
Trial: NCT01995656
Drug: Placebo - Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01995656
Drug: LY3108743 - Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01995656
Drug: Placebo - Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01995656
Drug: LY3108743 - Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00110721
Drug: GM-CT-01 plus 5-Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single use vials, combined regimen of GM-CT-01 / 5-Fluorouracil (280 mg/m2 /500 mg/m2) given for 4 consecutive days in a 28 day cycle until disease progression.
Trial: NCT02121080
Drug: REGN2222(SAR438584)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02121080
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03237325
Drug: SGX942
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/mL SGX942 administered as a 4 minute IV infusion, twice per week starting within 3 days after initiating radiation therapy and continuing through 2 weeks after radiation therapy ends.
Trial: NCT03237325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is 0.9% sodium chloride (normal saline). The treatment preparation, frequency and duration of therapy are identical to that of the active drug.
Trial: NCT01993238
Drug: Pre-treatment analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
Trial: NCT00734318
Drug: Flutiform 250/10 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00734318
Drug: Flutiform 50/5 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00734318
Drug: Flixotide pMDI 250 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02332044
Drug: Erdos, Talion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule 300mg and tablet 10mg
Trial: NCT02210494
Drug: Secretrol
RxNorm normalized name: gonorrheal urethral secretion human
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00653926
Drug: ropivacaine, ketorelac and epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Group A, 200 mg ropivicaine, 30 mg ketorelac and 0.5 mg epinephrine (total volume 106 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue After 21 postoperative hours in Group A, 150 mg ropivicaine, 30 mg ketorelac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
Trial: NCT05429385
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose, intravenous infusion
Trial: NCT01858935
Drug: ND-L02-s0201 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion.
Trial: NCT01858935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion.
Trial: NCT02967224
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT03616301
Drug: Clavamox
RxNorm normalized name: Clavamox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, manufactured by Pharmtechnology LLC, Belarus
Trial: NCT03616301
Drug: Augmentin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, marketed by CJSC GlaxoSmithKline Trading, Russia